|
Supportive care measures Clinical Trials
4 actively recruiting trials across 4 locations
Pipeline
Phase 3: 1Phase 1/2: 3
Top Sponsors
- Merck Sharp & Dohme LLC4
Indications
- Cancer4
- Pancreatic Ductal Adenocarcinoma1
- Esophageal Squamous Cell Carcinoma1
- Biliary Tract Cancer1
- Non-Muscle Invasive Bladder Cancer1
Phoenix, Arizona1 trial
Tucson, Arizona1 trial
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)
Phase 1/2
Bakersfield, California1 trial
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Michael G Oefelein Clinical Trials ( Site 0053)
Phase 1/2
Los Angeles, California1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.